Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Staar Surgical ( (STAA) ) has provided an update.
On August 4, 2025, STAAR Surgical Company entered into a merger agreement with Alcon, where STAAR will become a wholly owned subsidiary of Alcon. However, the merger has faced legal challenges as two lawsuits were filed by STAAR stockholders alleging misrepresentation in the proxy statement. Despite these challenges, STAAR plans to supplement the proxy statement to provide additional information to stockholders. The outcome of these legal matters remains uncertain, but STAAR believes the claims are without merit and aims to proceed with the merger to enhance shareholder value.
The most recent analyst rating on (STAA) stock is a Hold with a $28.00 price target. To see the full list of analyst forecasts on Staar Surgical stock, see the STAA Stock Forecast page.
Spark’s Take on STAA Stock
According to Spark, TipRanks’ AI Analyst, STAA is a Neutral.
Staar Surgical’s overall stock score is primarily impacted by financial struggles, with declining revenues and negative margins being significant concerns. Technical analysis shows bullish momentum, but valuation remains weak due to negative profitability. The earnings call provides some optimism with strategic initiatives, but challenges in China and profitability issues weigh heavily.
To see Spark’s full report on STAA stock, click here.
More about Staar Surgical
STAAR Surgical Company operates in the medical device industry, focusing on the development and manufacturing of implantable lenses for the eye, primarily used in vision correction procedures.
Average Trading Volume: 1,604,063
Technical Sentiment Signal: Hold
Current Market Cap: $1.32B
Learn more about STAA stock on TipRanks’ Stock Analysis page.